MELISSA STIPP: Open Payments
NPI 1922676204 · LEXINGTON, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$572 in 37 payments from 13 companies in 2025. Trend: 2023 $107 · 2024 $378 · 2025 $572
Food & beverage: $572
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $172 |
| Axsome Therapeutics, Inc. | 6 | $110 |
| Vanda Pharmaceuticals Inc. | 3 | $66 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $53 |
| GENZYME CORPORATION | 1 | $29 |
| Corcept Therapeutics | 1 | $24 |
| Indivior Inc. | 1 | $21 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Madrigal Pharmaceuticals | 1 | $16 |
Products named: Auvelity, VRAYLAR, FANAPT, CAPLYTA, RINVOQ, DUPIXENT, QULIPTA, Korlym.
Industry payments across KY — which companies pay providers there.
